P2.03a-058 is There a Place for Pemetrexed Rechallenge in Advanced Lung Adenocarcinoma?: Topic: Clinical Trials

Shen Lan,Shun Lu

DOI: https://doi.org/10.1016/j.jtho.2016.11.1268

IF: 20.121

2017-01-01

Journal of Thoracic Oncology

Abstract:There is a lot of lung cancer patients progressing beyond the third or fourth line of treatment still suitable for further therapy. Some patients choose to receive previous chemotherapy rechallenge, particularly in patients who had previously responded. So the role of chemotherapy rechallenge is worth discussing. Pemetrexed is known to be a potent chemotherapeutic agent with high efficacy and low toxicity in the treatment of advanced lung adenocarcinoma. In clinical practice, it is used to rechallenge by certain patients, according to previous efficacy and tolerance, as long as it was stopped for reasons other than progression. Therefore, the aim of this retrospective study is to evaluate the efficacy and safety of pemetrexed rechallenge strategy in lung adenocarcinoma. We retrospectively identified patients with the following criteria: (i) clinical benefit (stable disease (SD) or partial response (PR)) from previous line of pemetrexed-based chemotherapy (ii) discontinuation for a reason other than progression (iii) rechallenge with pemetrexed after a minimal pemetrexed-based chemotherapy-free interval of 3 months. The main objectives were to evaluate disease control rate (DCR),progression-free survival (PFS), overall survival (OS) and toxicity of pemetrexed rechallenge. 62 patients were enrolled into this study. Initial pemetrexed-based therapy was used as 1st or 2nd line of chemotherapy in 46 (74.2%), and 16 (25.8%)of cases. 43 (69.4%) patients achieved SD, 19 (30.6%) achieved PR. Pemetrexed was rechallenged as a 2nd, 3rd,or further line of chemotherapy in 43.5%, 37.1% and 19.4% of cases.4 patients (6.5%) achieved PR, 41 (66.1%) achieved SD and 17 (27.4%) experienced progressive disease. The median PFS was 3.9 months with the pemetrexed rechallenge. The median OS from the beginning of pemetrexed rechallenge was 8.2 months (95% CI: 5.0-11.3months). 38 (61.3%) patients had chance to receive further therapy after pemetrexed challenge failure. Next, we associated DCR,PFS,OS of pemetrexed rechallenge with the clinical outcomes of initial pemetrexed treatment. We found that patients who had longer PFS (P=0.036)or achieved PR response(P=0.022) to initial pemetrexed were more likely to get benefit from rechallenge. The patients with longer PFS of initial treatment exhibited longer PFS of rechallenge (P=0.008). However, the interval time between initial and rechallenge treatment did not affect efficacy of pemetrexed rechallenge. 25 patients (40%) reported grade 1/2 toxicity, 4 patients (6%) experienced grade3/4 toxicity, mostly neutropenia (65%) and hepatobiliary disorder (24%). It is a pragmatic strategy to retreat patients with pemetrexed when this drug has shown previous activity. The rechallenge treatment is generally well tolerated.